December 10, 2012

CAS databases provide millions of journal article references from more than 10,000 major scientific journals worldwide, patent and patent family references from 63 patent authorities around the world, and other reputable web sources.  

The following patent record is from the CAplusSM database.

CAPLUS COPYRIGHT 2012 ACS

Patent Number: WO 2012130780
Title: Preparation of thiazolopyrimidine derivatives for use as SYK inhibitors
Inventor(s): Hermann, Johannes Cornelius; Lowrie, Lee Edwin, Jr.; Lucas, Matthew C.; Luk, Kin-Chun Thomas; Padilla, Fernando; Wanner, Jutta; Xie, Wenwei; Zhang, Xiaohu
Patent Assignee(s): F. Hoffmann-La Roche AG, Switz.
Source: PCT Int. Appl., 162pp. CODEN: PIXXD2
Language: English

Abstract:

Title compds. I [B = Ph, pyridinyl, pyrrolidinyl, or piperidinyl; X = OH, alkyl, CONH2, etc.; R1 = (un)substituted Ph], and their pharmaceutically acceptable salts, are prepared and disclosed as SYK inhibitors.  Thus, e.g., II was prepared by amination of 5,7-dichlorothiazolo[5,4-d]pyrimidine with 3,4-dimethoxyphenylamine followed by coupling with 3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzoic acid Me ester, and hydrolysis.  Select I were evaluated in spleen tyrosine kinase (H-SYK-GST-SF9-C inactive-dephosphorylated) inhibition assays, e.g., II demonstrated an IC50 value of 0.421 uM.

View the full-text patent here.


Note: Titles and abstracts for patent records in CAplus are routinely enhanced to better describe the claimed invention. In this example, CAS enhanced both the abstract and title using additional information found in the patent. The original title of the PCT application is Thiazolopyrimidine compounds . For the CAplus record, this title was enhanced to read Preparation of thiazolopyrimidine derivatives for use as SYK inhibitors.

Recent News


    August 7, 2015 | CAS Announces the 2015 SciFinder
    Future Leaders in Chemistry and First-Ever Alumni
    Program
   
    August 3, 2015 | New STN Breaks Ground with
    Markush Structure Search and Enhanced Content
    for Intellectual Property Exploration and Research
   
    June 29, 2015 | CAS Assigns the 100 Millionth CAS
    Registry Number to a Substance Designed to
    Treat Acute Myeloid Leukemia
   
                                                                       More News >> 
 
 

Media Contact

 Name: Rhonda Ross
 Phone: 614-447-3624
 Email: cas-pr@cas.org